Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,648 recruiting studies in this area right now.
By phase
- Not applicable9,813
- Phase 24,456
- Phase 12,744
- Phase 1/Phase 21,689
- Phase 31,402
- Phase 2/Phase 3281
- Phase 4263
Top conditions
- Breast Cancer1,229
- Cancer660
- Prostate Cancer656
- Colorectal Cancer493
- Lung Cancer426
- Ovarian Cancer341
- Multiple Myeloma330
- Gastric Cancer298
- Acute Myeloid Leukemia293
- Pancreatic Cancer292
- Hepatocellular Carcinoma284
- Solid Tumor258
- Advanced Solid Tumor257
- Cervical Cancer232
- Head and Neck Cancer227
- Endometrial Cancer206
- Advanced Solid Tumors195
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center452
- Fudan University315
- Sun Yat-sen University291
- Memorial Sloan Kettering Cancer Center288
- National Cancer Institute (NCI)287
- Mayo Clinic240
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center144
- AstraZeneca133
- University Health Network, Toronto125
Where studies are running
- California1,426
- Texas641
- Arizona510
- Florida450
- Alabama420
- New York410
- Massachusetts339
- Maryland330
- New Jersey269
- Pennsylvania240
Recruiting studies20,648 total
- NCT04872478RecruitingPhase 1
Early-phase drug safety and dosing study for relapsed blood cancers
This Phase 1 trial tests MRX-2843 in teenagers and adults whose leukemia has come back or did not respond to prior treatment. The main goals are to find safe dosing and learn how the body processes the drug.
Atlanta, GeorgiaAges 12 years+ - NCT04872543RecruitingPhase 2
Study drug for nerve tumor caused by PRC2 loss
This Phase 2 trial studies ASTX727 in people with malignant peripheral nerve sheath tumors (MPNST) that have a specific genetic change (“PRC2 loss”). It aims to shrink or control advanced tumors that have not responded to at least one standard treatment, by testing how well the drug works and is tolerated.
Basking Ridge, New JerseyAges 16 years+ - NCT04874064Recruiting
AI blood tests for triple-negative breast cancer after treatment
This study uses a computer (AI) to read results from blood tests to look for signs of remaining triple-negative breast cancer, before and/or after surgery. It may help doctors better detect residual tumor and guide follow-up care.
London, OntarioAges 18 years+ - NCT04875585RecruitingPhase 2
Neoadjuvant and post-surgery immunotherapy for operable lung cancer
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
Innsbruck, TyrolAges 18 years+ - NCT04875611RecruitingPhase 2
Nivolumab for nasopharyngeal cancer after platinum chemotherapy
This trial studies nivolumab (an immune therapy) for nasopharyngeal cancer that grew or returned after platinum chemotherapy. It aims to shrink tumors or slow cancer growth after standard treatment hasn’t worked.
BialystokAges 18 years+ - NCT04877522RecruitingPhase 4
Continued asciminib treatment for certain leukemia patients
This trial lets people who already have Philadelphia chromosome–positive (Ph+) leukemia and are benefiting from asciminib (or certain related medicines) continue treatment. It mainly tests whether ongoing care in a follow-on study is safe and workable for participants.
Ann Arbor, MichiganAges 7–100 - NCT04878029RecruitingPhase 1
Cabozantinib plus enfortumab for advanced bladder cancer after immunotherapy
This Phase 1 study tests whether cabozantinib combined with enfortumab vedotin can help people with advanced urothelial (bladder) cancer that has already been treated with immunotherapy (PD-1/PD-L1) and usually chemotherapy. It aims to find a safer dose and see if the combo can shrink tumors or control the disease.
Atlanta, GeorgiaAges 18 years+ - NCT04878666Recruiting
Breast cancer chest-wall recurrence quality of life with heat treatment
This trial studies how a special heating radiation treatment (“hyperthermia radiotherapy”) affects quality of life in people whose breast cancer has come back in the chest area. It may help show whether this treatment approach is tolerable and beneficial for everyday well-being.
Tübingen, Baden-WurttembergAges 18 years+ - NCT04880356Recruiting
Study of very rare inherited brain diseases over time
This study follows adults over time who have a very rare inherited brain disease, or whose illness seems like it may run in families. The goal is to better understand these conditions and how they progress.
Milan, MilanoAges 18 years+ - NCT04883437RecruitingPhase 2
Acalabrutinib plus obinutuzumab for slow-growing lymphoma
This Phase 2 study tests two medicines together—acalabrutinib and obinutuzumab—in people with previously untreated, slow-growing B-cell lymphomas. It aims to shrink the lymphoma and improve disease control, especially when tumor burden is low or when standard first treatments aren’t suitable.
Atlanta, GeorgiaAges 18 years+ - NCT04883671Recruiting
SBRT to treat a few spots of adenoid cystic cancer
This trial tests whether focused radiation (SBRT) can help control adenoid cystic carcinoma that has spread to a small number of places (oligometastatic disease). If you qualify, the study will treat up to 1–5 metastatic spots that doctors think can be safely targeted, to help control the cancer locally.
San Francisco, CaliforniaAges 18 years+ - NCT04888039Recruiting
Living with myeloma follow-up study in West-Occitanie
This study follows people with symptomatic multiple myeloma who live in the West-Occitanie region. It aims to better understand patients’ experiences and needs over time, which may help improve care and support.
Toulouse, West-OccitanieAges 18 years+ - NCT04886986RecruitingPhase 1
Testing a targeted radiation pill for advanced prostate cancer
This Phase 1 trial tests a small-molecule treatment that carries radioactive material to help treat prostate cancer that has spread and keeps growing despite standard hormone-blocking treatment. It’s mainly looking to find a safe dose and see how well the approach works in people with limited treatment options.
Brooklyn, New YorkAges 18–99 - NCT04886635Recruiting
Surgery timing after chemoradiation for esophageal cancer
This study looks at whether having surgery at the right time after chemoradiation improves outcomes for people with esophageal cancer. You might qualify if you have had (or are planning) chemoradiation and then are going to have surgery to remove the tumor.
Rotterdam, South HollandAges 18 years+ - NCT04888338Recruiting
Studying outcomes after CAR-T, radiation, or bispecific therapy
This study looks at how people with blood cancers do after they receive CAR-T therapy, radiation therapy, and/or bispecific therapy. It may help doctors understand which treatment combinations work best and what side effects to expect.
Houston, TexasAges 18 years+ - NCT04888481RecruitingPhase 2
Scan with a marker to find certain slow-growing tumors
This study tests an imaging scan using a special tracer (68Ga-HA-DOTATATE) to look for tumors that have somatostatin receptors. It may help doctors better locate suspected tumor sites so treatment planning can be more accurate.
Edmonton, AlbertaAges Any age - NCT04888741RecruitingPhase 2
Trial testing reduced immune T cells before stem cell transplant
This Phase 2 trial looks at a transplant approach that reduces harmful immune cells (T cells) before or during an allogeneic stem cell transplant. It may help lower the risk of transplant complications while still letting the donor immune system fight the blood cancer.
Cardiff, WalesAges 16–70 - NCT04889716RecruitingPhase 2
CAR-T followed by antibody treatment for lymphoma
This Phase 2 study looks at giving CAR-T cell therapy first, then follow-up “bispecific” antibody medicines to help keep large B-cell lymphoma from coming back. It’s for people whose lymphoma returned or did not respond to prior standard treatments and who still have measurable disease on scans.
Omaha, NebraskaAges 18 years+ - NCT04890171Recruiting
Endoscopic removal vs surgery for early stomach cancer type
This trial compares two ways to treat early stomach cancer: removing it through an endoscope versus doing an operation. It’s meant for a specific stomach-cancer type (undifferentiated) that has not spread, to see which approach may be better.
Goyang-si, Gyeonggi-doAges 19–75 - NCT04891289RecruitingPhase 2
Gemcitabine and oxaliplatin with a chemotherapy pump for bile duct cancer
This Phase 2 study tests gemcitabine plus oxaliplatin chemotherapy, and whether adding a chemotherapy pump (with floxuridine and dexamethasone) delivered to the liver improves outcomes. It is for people whose intrahepatic cholangiocarcinoma cannot be removed with surgery.
Bethesda, MarylandAges 18 years+ - NCT04890613RecruitingPhase 1
CX-5461 for cancers with BRCA or HRD gene changes
This Phase 1 trial tests CX-5461, a new cancer medicine, in people with certain solid tumors that have BRCA1/2 or related “HRD” gene mutations. The goal is to find out how the drug works, what dose is tolerable, and whether it can help shrink tumors.
Santa Monica, CaliforniaAges 18 years+ - NCT04891029Recruiting
Early detection testing for uterine or ovarian cancer risk
This study looks for early signs of uterine (endometrial) or ovarian cancer, especially in people with inherited risk. It may help doctors catch problems earlier, when treatment can be more effective.
Montreal, QuebecAges 45–75 - NCT04892849Recruiting
PD-1/PD-L1 immunotherapy plus radiation for solid tumors
This study tests whether combining an immune system medicine (PD-1/PD-L1 inhibitor) with radiation can improve outcomes in people with certain solid cancers. It also looks for blood or tissue “biomarkers” that may explain who benefits most.
Erlangen, BavariaAges 18 years+ - NCT04891068RecruitingPhase 2
Pre-surgery low-dose azacitidine for high-risk early breast cancer
This trial studies whether giving a low dose of azacitidine before surgery can shrink or control high-risk early breast cancer. It’s meant for adults whose cancer has not yet spread to distant organs.
Chicago, IllinoisAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,648 recruiting oncology studies from the U.S. registry right now, out of 31,565 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.